How does it differ from a conventional beta-blocker?

In having two actions rather than one. Classic beta-blockers slow the heart and reduce cardiac work, but through beta2 blockade they also cause mild vasoconstriction. That contributes to the characteristic complaints: cold hands and feet, fatigue, erectile dysfunction. Nebivolol additionally releases nitric oxide in the vessel wall, producing vasodilation that offsets those effects. The Weiss 2006 review and the Münzel 2009 JACC paper discuss this difference. The practical consequence is that many patients tolerate it better, which is no small consideration in long-term therapy.

Why is the bioavailability range so wide?

Because nebivolol is cleared by the CYP2D6 enzyme, whose activity is genetically determined and highly variable. Most people are so-called extensive metabolisers: the liver clears most of the drug on first pass, giving a bioavailability of about 12%. Roughly 7-10% of people, however, are poor metabolisers in whom that clearance barely operates and bioavailability can reach 96%. The same 5 mg can therefore produce plasma levels differing by an order of magnitude between two people. In practice this rarely requires genetic testing, because the physician titrates on clinical response, chiefly pulse and blood pressure, but it explains why some react unusually strongly.

Clinical ResearchResearch compound

Nebivolol (Nebilet, Bystolic)

Name: Nebivolol (Nebilet, Bystolic)
Creator: MolekulaX

A highly beta1-selective blocker that additionally releases nitric oxide, giving it a vasodilatory action. It causes less fatigue and erectile dysfunction than classic beta-blockers.

Available at

DEUSPOWERProduct page

Nebivolol 5 mg (tablets)

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

WHAT IS NEBIVOLOL (NEBILET, BYSTOLIC)?

Detailed overview

Nebivolol has two actions, and that duality gives it its clinical profile. The first is classical: highly selective beta1-adrenergic blockade, slowing heart rate and reducing cardiac work. Its selectivity is among the highest in the class, which limits unwanted effects on the airways and peripheral vessels. The second action is what sets it apart: nebivolol triggers nitric oxide release in the vascular endothelium and thereby causes vasodilation. The reviews by Maffei 2009 and Münzel 2009 discuss this mechanism in detail. Its practical significance is considerable, because classic beta-blockers do the opposite: through beta2 blockade they cause mild vasoconstriction, contributing to cold extremities, fatigue and erectile dysfunction. With nebivolol the vasodilatory component offsets this, and according to the Weiss 2006 review this explains the more favourable tolerability profile. The backbone of the clinical evidence is SENIORS (Flather 2005), which randomised heart failure patients over 70 to nebivolol or placebo and showed a reduction in the composite endpoint of death or cardiovascular hospitalisation. This matters because earlier beta-blocker trials largely excluded the elderly, often preserved-ejection-fraction heart failure population. One pharmacokinetic peculiarity deserves separate emphasis: nebivolol is cleared by CYP2D6, and that enzyme's activity varies strongly by genotype. In extensive metabolisers bioavailability is about 12%, while in poor metabolisers it can reach 96%. This eightfold difference explains why some people respond unusually strongly to the same dose.

Dual action

Strong beta1-selective blockade plus nitric-oxide-mediated vasodilation.

Why better tolerated

The vasodilatory component offsets the cold extremities and fatigue typical of beta-blockers.

Outcome data

SENIORS: reduced death or cardiovascular hospitalisation in elderly heart failure.

Genetic variability

CYP2D6-dependent: bioavailability ranges from 12% to 96% by metaboliser status.

Dosing

5 mg once daily for hypertension; slow titration from 1.25 mg in heart failure.

Data console

Lab data

/lab/molecular-data.jsonLIVE
> ATC code-
> PrescriptionN/A
> MechanismNebivolol acts in two independent ways. First, it is a comp…
> Half-lifeAbout 10 hours in extensive CYP2D6 metabolisers and several times longer, above 30 hours, in poor metabolisers. Once-daily dosing suffices in both cases.
> OnsetThe antihypertensive effect is noticeable within days, with the full effect over one to two weeks. In heart failure titration takes weeks.
> BioavailabilityExtremely genotype-dependent: about 12% in extensive CYP2D6 metabolisers and up to 96% in poor metabolisers. This nearly eightfold difference is nebivolol's most important pharmacokinetic feature and explains why the same dose produces a substantially stronger effect and more adverse effects in some patients.

Safety

Side effects, stop signs, contraindications

Side effects · 4

Fatigue and dizziness: familiar beta-blocker complaints, but typically milder with nebivolol than with classic agents because of the vasodilatory action.
Slowing heart rate: an intrinsic part of the effect, but excessive bradycardia requires dose reduction. A resting pulse below 50 needs medical assessment.
Headache and peripheral edema: consequences of the vasodilatory component, usually mild.
In slow CYP2D6 metabolisers plasma levels can be many times the usual, so adverse effects are more pronounced. This is roughly 7-10% of people of European ancestry.

Contraindications · 4

Decompensated heart failure, cardiogenic shock, second or third degree AV block, sick sinus syndrome and severe bradycardia: absolute contraindications.
Severe hepatic impairment: clearance slows substantially, contraindicated.
Asthma and severe obstructive lung disease: beta1 selectivity is high but not absolute, so caution or avoidance is warranted.
Abrupt discontinuation: beta-blockers must be tapered, as sudden cessation can provoke angina or arrhythmia.

Related Pharmaceuticals

Same therapeutic category

Studies

Related research and clinical findings

European heart journal

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

Flather MD, Shibata MC, Coats AJ

PMID: 15642700Open

Vascular health and risk management

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.

Weiss R

PMID: 17326335Open

Therapeutic advances in cardiovascular disease

Nitric oxide mechanisms of nebivolol.

Maffei A, Lembo G

PMID: 19443516Open

Journal of the American College of Cardiology

Nebivolol: the somewhat-different beta-adrenergic receptor blocker.

Münzel T, Gori T

PMID: 19815121Open

Have a question about Nebivolol (Nebilet, Bystolic)?

Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.